Pashtun Shahim1, Adam Politis2, Andre van der Merwe2, Brian Moore2, Vindhya Ekanayake2, Sara M Lippa2, Yi-Yu Chou2, Dzung L Pham2, John A Butman2, Ramon Diaz-Arrastia2, Henrik Zetterberg2, Kaj Blennow2, Jessica M Gill2, David L Brody2, Leighton Chan2. 1. From the NIH (P.S., A.P., S.M.L., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., V.E., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., V.E., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; National Intrepid Center of Excellence (S.M.L.) and Defense and Veterans Brain Injury Center (S.M.L.), Walter Reed National Military Medical Center, Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK; and Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD. pashtun-poh.shahim@nih.gov. 2. From the NIH (P.S., A.P., S.M.L., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., V.E., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., V.E., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; National Intrepid Center of Excellence (S.M.L.) and Defense and Veterans Brain Injury Center (S.M.L.), Walter Reed National Military Medical Center, Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK; and Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD.
Abstract
OBJECTIVE: To determine whether neurofilament light (NfL), glial fibrillary acidic protein (GFAP), tau, and ubiquitin C-terminal hydrolase-L1 (UCH-L1) measured in serum relate to traumatic brain injury (TBI) diagnosis, injury severity, brain volume, and diffusion tensor imaging (DTI) measures of traumatic axonal injury (TAI) in patients with TBI. METHODS: Patients with TBI (n = 162) and controls (n = 68) were prospectively enrolled between 2011 and 2019. Patients with TBI also underwent serum, functional outcome, and imaging assessments at 30 (n = 30), 90 (n = 48), and 180 (n = 59) days, and 1 (n = 84), 2 (n = 57), 3 (n = 46), 4 (n = 38), and 5 (n = 29) years after injury. RESULTS: At enrollment, patients with TBI had increased serum NfL compared to controls (p < 0.0001). Serum NfL decreased over the course of 5 years but remained significantly elevated compared to controls. Serum NfL at 30 days distinguished patients with mild, moderate, and severe TBI from controls with an area under the receiver-operating characteristic curve (AUROC) of 0.84, 0.92, and 0.92, respectively. At enrollment, serum GFAP was elevated in patients with TBI compared to controls (p < 0.001). GFAP showed a biphasic release in serum, with levels decreasing during the first 6 months of injury but increasing over the subsequent study visits. The highest AUROC for GFAP was measured at 30 days, distinguishing patients with moderate and severe TBI from controls (both 0.89). Serum tau and UCH-L1 showed weak associations with TBI severity and neuroimaging measures. Longitudinally, serum NfL was the only biomarker that was associated with the likely rate of MRI brain atrophy and DTI measures of progression of TAI. CONCLUSIONS: Serum NfL shows greater diagnostic and prognostic utility than GFAP, tau, and UCH-L1 for subacute and chronic TBI. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that serum NfL distinguishes patients with mild TBI from healthy controls.
OBJECTIVE: To determine whether neurofilament light (NfL), glial fibrillary acidic protein (GFAP), tau, and ubiquitin C-terminal hydrolase-L1 (UCH-L1) measured in serum relate to traumatic brain injury (TBI) diagnosis, injury severity, brain volume, and diffusion tensor imaging (DTI) measures of traumatic axonal injury (TAI) in patients with TBI. METHODS: Patients with TBI (n = 162) and controls (n = 68) were prospectively enrolled between 2011 and 2019. Patients with TBI also underwent serum, functional outcome, and imaging assessments at 30 (n = 30), 90 (n = 48), and 180 (n = 59) days, and 1 (n = 84), 2 (n = 57), 3 (n = 46), 4 (n = 38), and 5 (n = 29) years after injury. RESULTS: At enrollment, patients with TBI had increased serum NfL compared to controls (p < 0.0001). Serum NfL decreased over the course of 5 years but remained significantly elevated compared to controls. Serum NfL at 30 days distinguished patients with mild, moderate, and severe TBI from controls with an area under the receiver-operating characteristic curve (AUROC) of 0.84, 0.92, and 0.92, respectively. At enrollment, serum GFAP was elevated in patients with TBI compared to controls (p < 0.001). GFAP showed a biphasic release in serum, with levels decreasing during the first 6 months of injury but increasing over the subsequent study visits. The highest AUROC for GFAP was measured at 30 days, distinguishing patients with moderate and severe TBI from controls (both 0.89). Serum tau and UCH-L1 showed weak associations with TBI severity and neuroimaging measures. Longitudinally, serum NfL was the only biomarker that was associated with the likely rate of MRI brain atrophy and DTI measures of progression of TAI. CONCLUSIONS: Serum NfL shows greater diagnostic and prognostic utility than GFAP, tau, and UCH-L1 for subacute and chronic TBI. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that serum NfL distinguishes patients with mild TBI from healthy controls.
Authors: Pierre-Louis Bazin; Chuyang Ye; John A Bogovic; Navid Shiee; Daniel S Reich; Jerry L Prince; Dzung L Pham Journal: Neuroimage Date: 2011-06-21 Impact factor: 6.556
Authors: Grant L Iverson; Preethi J Reddi; Jussi P Posti; Anna-Kerttu Kotilainen; Olli Tenovuo; Juha Öhman; Henrik Zetterberg; Kaj Blennow; Teemu M Luoto Journal: J Neurotrauma Date: 2019-04-23 Impact factor: 5.269
Authors: D H Smith; X H Chen; J E Pierce; J A Wolf; J Q Trojanowski; D I Graham; T K McIntosh Journal: J Neurotrauma Date: 1997-10 Impact factor: 5.269
Authors: Benjamin Y Gravesteijn; Charlie A Sewalt; Ari Ercole; Cecilia Akerlund; David Nelson; Andrew I R Maas; David Menon; Hester F Lingsma; Ewout W Steyerberg Journal: J Neurotrauma Date: 2019-12-05 Impact factor: 5.269
Authors: Linda Papa; Gretchen M Brophy; Robert D Welch; Lawrence M Lewis; Carolina F Braga; Ciara N Tan; Neema J Ameli; Marco A Lopez; Crystal A Haeussler; Diego I Mendez Giordano; Salvatore Silvestri; Philip Giordano; Kurt D Weber; Crystal Hill-Pryor; Dallas C Hack Journal: JAMA Neurol Date: 2016-05-01 Impact factor: 18.302
Authors: William R McBride; Caroline E Conlan; Nicole A Barylski; Amelie C Warneryd; Randel L Swanson Journal: Curr Phys Med Rehabil Rep Date: 2022-02-26
Authors: Pashtun Shahim; Henrik Zetterberg; Joel Simrén; Nicholas J Ashton; Gina Norato; Michael Schöll; Yelverton Tegner; Ramon Diaz-Arrastia; Kaj Blennow Journal: Neurology Date: 2022-06-02 Impact factor: 11.800
Authors: Linda Papa; Alexa E Walter; James R Wilkes; Hunter S Clonts; Brian Johnson; Semyon M Slobounov Journal: J Neurotrauma Date: 2022-09-01 Impact factor: 4.869
Authors: Nathan H Johnson; Roey Hadad; Ruby Rose Taylor; Javier Rodríguez Pilar; Osman Salazar; Juan Antonio Llompart-Pou; W Dalton Dietrich; Robert W Keane; Jon Pérez-Bárcena; Juan Pablo de Rivero Vaccari Journal: Pharmaceuticals (Basel) Date: 2022-05-25
Authors: Min-Kyoo Shin; Edwin Vázquez-Rosa; Yeojung Koh; Matasha Dhar; Kalyani Chaubey; Coral J Cintrón-Pérez; Sarah Barker; Emiko Miller; Kathryn Franke; Maria F Noterman; Divya Seth; Rachael S Allen; Cara T Motz; Sriganesh Ramachandra Rao; Lara A Skelton; Machelle T Pardue; Steven J Fliesler; Chao Wang; Tara E Tracy; Li Gan; Daniel J Liebl; Jude P J Savarraj; Glenda L Torres; Hilda Ahnstedt; Louise D McCullough; Ryan S Kitagawa; H Alex Choi; Pengyue Zhang; Yuan Hou; Chien-Wei Chiang; Lang Li; Francisco Ortiz; Jessica A Kilgore; Noelle S Williams; Victoria C Whitehair; Tamar Gefen; Margaret E Flanagan; Jonathan S Stamler; Mukesh K Jain; Allison Kraus; Feixiong Cheng; James D Reynolds; Andrew A Pieper Journal: Cell Date: 2021-04-13 Impact factor: 41.582
Authors: David F Tate; Emily L Dennis; John T Adams; Maheen M Adamson; Heather G Belanger; Erin D Bigler; Heather C Bouchard; Alexandra L Clark; Lisa M Delano-Wood; Seth G Disner; Blessen C Eapen; Carol E Franz; Elbert Geuze; Naomi J Goodrich-Hunsaker; Kihwan Han; Jasmeet P Hayes; Sidney R Hinds; Cooper B Hodges; Elizabeth S Hovenden; Andrei Irimia; Kimbra Kenney; Inga K Koerte; William S Kremen; Harvey S Levin; Hannah M Lindsey; Rajendra A Morey; Mary R Newsome; John Ollinger; Mary Jo Pugh; Randall S Scheibel; Martha E Shenton; Danielle R Sullivan; Brian A Taylor; Maya Troyanskaya; Carmen Velez; Benjamin Sc Wade; Xin Wang; Ashley L Ware; Ross Zafonte; Paul M Thompson; Elisabeth A Wilde Journal: Brain Imaging Behav Date: 2021-01-07 Impact factor: 3.978
Authors: Pashtun Shahim; Adam Politis; Andre van der Merwe; Brian Moore; Yi-Yu Chou; Dzung L Pham; John A Butman; Ramon Diaz-Arrastia; Jessica M Gill; David L Brody; Henrik Zetterberg; Kaj Blennow; Leighton Chan Journal: Neurology Date: 2020-07-08 Impact factor: 9.910
Authors: Zac Chatterton; Natalia Mendelev; Sean Chen; Walter Carr; Gary H Kamimori; Yongchao Ge; Andrew J Dwork; Fatemeh Haghighi Journal: Front Mol Neurosci Date: 2021-07-02 Impact factor: 6.261
Authors: Sima Azizi; Daniel B Hier; Blaine Allen; Tayo Obafemi-Ajayi; Gayla R Olbricht; Matthew S Thimgan; Donald C Wunsch Journal: Front Neurol Date: 2021-07-06 Impact factor: 4.003